» Articles » PMID: 12445535

One-year Mortality Among Unselected Outpatients with Heart Failure

Overview
Journal Eur Heart J
Date 2002 Nov 26
PMID 12445535
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To estimate 1-year mortality and prognostic factors in unselected outpatients with heart failure, and to compare the observed mortality with the estimates of the primary care physicians.

Methods And Results: Four hundred and eleven consecutive patients with heart failure New York Heart Association (NYHA) class II-IV (mean population age 75 years, 56% males) were enrolled in 71 primary care offices throughout Switzerland. During a mean follow-up period of 1.4 years, 68 patients had died. One-year total mortality was 12.6% compared to 4.3% in the underlying Swiss population (standardized mortality ratio 3.0). Among patients with heart failure NYHA II, III and IV, mortality was 7.1%, 15.0% and 28.0%, respectively. In multivariate Cox regression, statistically significant (P<0.05) predictors of mortality were NYHA class (NYHA III: risk ratio [RR]=1.6; NYHA IV: RR=2.2), recent hospital stay for heart disease (RR=2.3), creatinine>120 micromol.l(-1) (RR=1.8) systolic blood pressure<100 mmHg (RR=2.4), heart rate>100 min(-1) (RR=2.7), age (per 10 years, RR=1.6) and female gender (RR=0.49). Among patients with reduced left ventricular ejection fraction, 1-year mortality was 14.3%, and predictors were similar except that female gender was no longer associated with reduced mortality. Primary care physicians significantly overestimated 1-year mortality (estimated mortality 25.9% vs observed mortality 12.6%,P =0.001).

Conclusions: Unselected outpatients with heart failure have a poor prognosis, particularly those with advanced heart failure and a recent hospital stay for heart disease. Primary care physicians are aware of the high mortality of this growing patient population.

Citing Articles

Evolution of the Quality of Care in Patients with Decompensated Heart Failure in a Venezuelan Hospital.

Torres Y, Benitez D, Morillo Z, Salazar J, Contreras-Velasquez J, Bermudez V J Clin Med. 2025; 14(2).

PMID: 39860650 PMC: 11765786. DOI: 10.3390/jcm14020644.


Improvements in Efficacy Measures With Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial.

Hanna M, Fine N, Gundapaneni B, Sultan M, Witteles R JACC Adv. 2024; 1(5):100148.

PMID: 38939456 PMC: 11198604. DOI: 10.1016/j.jacadv.2022.100148.


Association of NT-proBNP and sST2 with Left Ventricular Ejection Fraction and Oxidative Stress in Patients with Stable Dilated Cardiomyopathy.

Lazar-Poloczek E, Romuk E, Jachec W, Wrobel-Nowicka K, Swietek A, Wojciechowska C Biomedicines. 2024; 12(4).

PMID: 38672063 PMC: 11048168. DOI: 10.3390/biomedicines12040707.


Incremental Role of New York Heart Association Class and Cardiopulmonary Exercise Test Indices for Prognostication in Heart Failure: A Cohort Study.

Engster P, Zimerman A, Schaan T, Borges M, Souza G, Costa G Arq Bras Cardiol. 2023; 120(11):e20230077.

PMID: 38126514 PMC: 10773458. DOI: 10.36660/abc.20230077.


Prognostic Role of Metabolic Exercise Testing in Heart Failure.

Agdamag A, Van Iterson E, Tang W, Finet J J Clin Med. 2023; 12(13).

PMID: 37445473 PMC: 10342748. DOI: 10.3390/jcm12134438.